The peptide craze is outpacing the science

A peptide is a short protein. The body produces thousands of them, but only a small fraction circulate outside cells as signalling molecules. That fraction is what interests both pharmaceutical developers and the growing community of biohackers. The commentary on Fight Aging describes how a small number of partly studied peptides are now widely available, aided by a quirk in US regulation that allows compounding pharmacies to prepare substances without FDA approval for patient use.

Compounding pharmacies and a regulatory grey zone

In the US, compounding pharmacies operate under state rather than federal regulation. They can legally prepare a substance if a rigorous manufacturing protocol has been published, regardless of whether the FDA has approved it for clinical use. Many of the peptides currently being marketed fall into this grey zone. Additionally, the supplement industry is reportedly lobbying to bring peptides under its own, even more permissive regulatory framework.

The success of GLP-1 receptor agonists, which are also peptides but backed by robust clinical trial data, has amplified the broader hype. Critics argue that the comparison is misleading: most popular peptides have only animal studies behind them, or sometimes less.

Neither a blanket yes nor a blanket no

The author makes the point that current US drug regulation has its own serious problems, including delays in approving genuinely effective medicines. Stricter regulation is not automatically better. But that does not mean weak evidence equals evidence. For anyone considering peptides, the relevant question is which specific compounds have human trial data and which are driven primarily by marketing. In the current market, that distinction is difficult to make.

Read the original article